Oxford Nanopore announced 22% full‑year 2025 revenue growth after a strategic restructuring that narrowed product focus and reduced some R&D headcount. The company said it is prioritizing high‑priority opportunities and aligning resources to meet demand from clinical and biopharma customers. Separately, clinicians at CHOP and Seattle Children’s unveiled plans to implement ultra‑rapid nanopore sequencing assays for acute leukemia and CNS tumor diagnosis, promising same‑day genomic data for urgent clinical decisions. The moves together point to accelerating clinical adoption of real‑time long‑read sequencing in oncology diagnostics and a potential commercial tailwind for nanopore platforms. Nanopore sequencing reads long DNA/RNA strands electrically, enabling fast, flexible assays without PCR amplification.